anonymous
Guest
anonymous
Guest
Viiv, or GSK? Not sure how you can blame one and not the other when all the issues point to change of control.
Regardless, safe to say that Viiv brings more value than the GSK vax joint venture set up to distract from the rest of the circus. I cant wait for an adjuvant to gene therapies and one vaccine that remain unapproved by the FDA.
Actually, im more excited to see how the company pretends to be a real spec pharm bc is conducive to the narrative they need to fuel.
Maybe we can all figure out a way to be more diverse and less white to generate real value.
And here we go sideways with the white people insults